TG THERAPEUTICS, INC. Amortization of Debt Issuance Costs and Discounts
TG THERAPEUTICS, INC. (TGTX) reported Amortization of Debt Issuance Costs and Discounts of $300.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-05-06
- TG THERAPEUTICS, INC. amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $300.00K, a 0.00% change year-over-year.
- TG THERAPEUTICS, INC. amortization of debt issuance costs and discounts for the quarter ending 2025-03-31 was $300.00K.
- TG THERAPEUTICS, INC. amortization of debt issuance costs and discounts for the quarter ending 2011-09-30 was $887.20K, a 993.15% increase year-over-year.
- TG THERAPEUTICS, INC. amortization of debt issuance costs and discounts for the quarter ending 2010-09-30 was $81.16K.
- TG THERAPEUTICS, INC. amortization of debt issuance costs and discounts for fiscal 2025 was $1.20M, a 40.00% decline from fiscal 2024.
- TG THERAPEUTICS, INC. amortization of debt issuance costs and discounts for fiscal 2024 was $2.00M, a 16.67% decline from fiscal 2023.
- TG THERAPEUTICS, INC. amortization of debt issuance costs and discounts for fiscal 2023 was $2.40M.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month | Amortization of Debt Issuance Costs and Discounts 119 month | Amortization of Debt Issuance Costs and Discounts 122 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | $300.00K 10-Q · filed 2026-05-06 | |||||
| 2025-12-31 | $1.20M 10-K · filed 2026-02-27 | |||||
| 2025-03-31 | $300.00K 10-Q · filed 2026-05-06 | |||||
| 2024-12-31 | $2.00M 10-K · filed 2026-02-27 | |||||
| 2023-12-31 | $2.40M 10-K · filed 2026-02-27 | |||||
| 2011-09-30 | $887.20K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | $1.04M 10-Q · filed 2011-11-14 | $1.98M 10-Q · filed 2011-11-14 | |||
| 2011-06-30 | $154.55K 10-Q/A · filed 2011-09-14 | $1.09M 10-Q/A · filed 2011-09-14 | ||||
| 2010-09-30 | $81.16K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | $288.77K 10-Q · filed 2011-11-14 | ||||
| 2010-06-30 | $207.61K 10-Q/A · filed 2011-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |